La Roche-Posay Acne Treatment Recalled Over Benzene Contamination
L'Oreal USA has issued a nationwide voluntary recall of its La Roche-Posay Laboratoire Dermatologique Effaclar Duo Dual Action Acne Treatment following the detection of trace levels of benzene, a known human carcinogen. The affected product comes in 40 mL (1.35 fl oz) tubes, labeled with UPC 883140500759, and belongs to lot number MYX46W with an expiration date of April 30, 2025. A total of 2 226 801 units are included in this recall, which was initiated on March 5, 2025.
The US Food and Drug Administration (FDA) has classified the recall as Class II, indicating that exposure to the product may cause temporary or medically reversible adverse health consequences. Although no press release has been issued by the company, consignees have been notified by letter. The recall remains ongoing and was last classified by the FDA on May 9, 2025. The product was distributed nationwide across the US.
Effaclar Duo is an over-the-counter topical acne medication formulated with 5.5% benzoyl peroxide, designed to target and reduce acne blemishes and prevent new breakouts. Pharmacists are advised to check inventory for the specific lot number and assist in the removal of affected products from shelves. While the recall is precautionary, benzene exposure is a significant safety concern and warrants attention due to its association with blood disorders and cancer upon prolonged or high-level exposure.
